_{Introduction: The majority of all NETs develop in the GI
tract and about one}

_{third develop in the lungs; approximately 43%
and 51% of pts, respectively,}

_{are diagnosed with adv disease (regional or
distant metastasis). While GI and}

_{lung NETs are rare, their incidence has
increased markedly over the past four}

_{decades. The severe and progressive nature of
adv NET suggests significant}

_{costs for pts and payers. Aim(s): Describe the incidence and prevalence, and}

_{characterize HCRU and treatment modalities in
pts with adv WD NET of GI or}

_{lung origin in Southwest Finland. Materials and
methods: Retrospective data}

_{was collected from Auria Biobank (2004-2013).
Electronic records were used}

_{to identify pts with WD GI or lung NET (grade
1 and 2; Ki-67 <20%). Data on}

_{HCRU, including hospital treatment periods,
hospital days, outpatient visits,}

_{medical procedures, and laboratories were
collected. Results: 265 pts were}

_{diagnosed with NET. 99/265 (37%) pts had a WD
NET of GI or lung origin with}

_{an increasing incidence over the study period.
33/99 pts had an adv disease,}

_{and 14/33 a non-functional tumor. Most types
of HCRU were slightly higher}

_{among pts with non-functional tumors than pts
with functional tumors and the}

_{higher HCRU are exemplified by more inpatient
and outpatient visits per}

_{patient year. Somatostatin analogues (SSAs)
were administered in 19/30 pts,}

_{and usage was greater in pts with functional
NET; 3/30 pts received}

_{chemotherapy; none of the pts were treated
with interferon. Conclusion:}

_{There seems to be an increasing trend in the
incidence of lung or GI NET as}

_{previously described in the literature. These results indicate slightly higher}

_{HCRU in pts with non-functional than functional adv, WD GI and lung NET.}